1. YeastSaccharomyces cerevisiae as a model system to study the cytotoxic activity of the antitumor drug camptothecin

   • Mary-Ann Bjornsti
   • Anne M. Knab
   • Piero Benedetti

   Session 1: Topoisomerase Basic Science Pages: S1 - S5

2. Using yeast to study resistance to topoisomerase II-targeting drugs

   • John L. Nitiss

   Session 1: Topoisomerase Basic Science Pages: S6 - S13

3. Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells

   • William T. Beck
   • Ryungsa Kim
   • Mei Chen

   Session 1: Topoisomerase Basic Science Pages: S14 - S18

4. Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes

   • Neil Osheroff
   • Anita H. Corbett
   • Majken Westergaard

   Session 1: Topoisomerase Basic Science Pages: S19 - S25

5. Structure-activity relationships of VP-16 analogues

   • Byron H. Long
   • Anna-Maria Casazza

   Session 1: Topoisomerase Basic Science Pages: S26 - S31

6. Topoisomerase expression in cancer cell lines and clinical samples

   • L. Austin Doyle

   Session 1: Topoisomerase Basic Science Pages: S32 - S40

7. Preclinical and phase I trials of topoisomerase I inhibitors

   • Daniel D. Von Hoff
   • Howard A. Burris III
   • John G. Kuhn

   Session 2: Pharmacology: Preclinical and Phase I Studies of Topoisomerase Dosing Concepts Pages: S41 - S45

8. Clinical, pharmacokinetic and biological studies of topotecan

   • Peter J. O'Dwyer
   • Frank P. LaCreta
   • Kang-Shen Yao

   Session 2: Pharmacology: Preclinical and Phase I Studies of Topoisomerase Dosing Concepts Pages: S46 - S52

9. Camptothecin analogues: studies from The Johns Hopkins Oncology Center

   • William J. Slichenmyer
   • Eric K. Rowinsky
   • Ross C. Donehower

   Session 2: Pharmacology: Preclinical and Phase I Studies of Topoisomerase Dosing Concepts Pages: S53 - S57

10. Clinical and pharmacokinetic overview of parenteral etoposide phosphate

    • Lee P. Schacter
    • Linus N. Igwemezie
    • Pedro Santabárbara

    Session 2: Pharmacology: Preclinical and Phase I Studies of Topoisomerase Dosing Concepts Pages: S58 - S63

11. Pharmacodynamics and long-term toxicity of etoposide

    • Ken Kobayashi
    • Mark J. Ratain

    Session 2: Pharmacology: Preclinical and Phase I Studies of Topoisomerase Dosing Concepts Pages: S64 - S68

12. Etoposide dosage and pharmacodynamics

    • Simon P. Joel
    • Rita Shah
    • Maurice L. Slevin

    Session 2: Pharmacology: Preclinical and Phase I Studies of Topoisomerase Dosing Concepts Pages: S69 - S75

13. Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations

    • Clinton F. Stewart

    Session 2: Pharmacology: Preclinical and Phase I Studies of Topoisomerase Dosing Concepts Pages: S76 - S83

14. Schedule-dependent topoisomerase II-inhibiting drugs

    • Simon P. Joel
    • Maurice L. Slevin

    Session 2: Pharmacology: Preclinical and Phase I Studies of Topoisomerase Dosing Concepts Pages: S84 - S88

15. Epipodophyllotoxins in the treatment of childhood cancer

    • Gaston K. Rivera
    • Ching-Hon Pui
    • William M. Crist

    Session 3: Clinical Trials and Applications Pages: S89 - S95

16. Etoposide in the treatment of elderly/poor-prognosis patients with small-cell lung cancer

    • Desmond N. Carney
    • Anthony Byrne

    Session 3: Clinical Trials and Applications Pages: S96 - S100

17. Prolonged administration of low-daily-dose etoposide: a superior dosing schedule?

    • F. Anthony Greco
    • John D. Hainsworth

    Session 3: Clinical Trials and Applications Pages: S101 - S104

18. Clinical studies of irinotecan alone and in combination with cisplatin

    • Masahiro Fukuoka
    • Noriyuki Masuda

    Session 3: Clinical Trials and Applications Pages: S105 - S111

19. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials

    • Nagahiro Saijo
    • Kazuto Nishio
    • Makoto Nishio

    Session 3: Clinical Trials and Applications Pages: S112 - S117

20. Etoposide: current status and future perspectives in the management of malignant neoplasms

    • Chandra P. Belani
    • L. Austin Doyle
    • Joseph Aisner

    Session 3: Clinical Trials and Applications Pages: S118 - S126

21. Teniposide: overview of its therapeutic potential in adult cancers

    • Franco M. Muggia

    Session 3: Clinical Trials and Applications Pages: S127 - S133